Use of biologic therapies for psoriasis during pregnancy

Use of biologic therapies for psoriasis during pregnancy and long‐term outcomes of exposed children: A 14‐year real‐life experience at a tertiary center in Turkey and review of the literature:

ABSTRACT

Data regarding the use of biologic therapies for psoriasis during pregnancy are scarce with even more limited knowledge about the long‐term safety of in utero exposure. We retrospectively evaluated nine pregnancies in six women with psoriasis who were exposed to biologic therapies between 2006 and 2019 in our psoriasis clinic, a tertiary referral center in Turkey. Pregnancy outcomes included the delivery of seven healthy babies without any complications, one elective abortion, and one ectopic pregnancy. All exposed children, aged between 14 months and 13 years (median age: 4.0 years), showed normal growth and neuropsychological development without immunodeficiencies, allergies, malignancies or other diseases. Based on up‐to‐date collective data in the literature and our real‐life clinical experience presented here, exposure to biologic therapies during pregnancy for psoriasis does not seem to be associated with adverse pregnancy or neonatal outcomes. Our results are also reassuring with respect to long‐term outcomes of exposed children, but need to be confirmed through further large prospective studies. Nevertheless, use of biologic therapies during late pregnancy, particularly during the third trimester, should be reserved for high‐need patients with psoriasis and definitely requires a delicate risk/benefit balance on a case‐by‐case basis.

This article is protected by copyright. All rights reserved.